Home

Mary T Szela

CIK 1410289 · CEO and President · last filed 2026-07-06

Mary T Szela is a CEO and President who has filed 80 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing shows the insider bought $148.9K of ABSI on Jul 6, 2026. Across all open-market trades the lifetime net is −$7.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $23.7M across reported positions. 29 SEC filings were submitted jointly with LABORATORIES ABBOTT.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$23.70M

Companies

12

Total Filings

80

Lifetime Open-Market Net

-$7.54M

Filer Profile

Reported Address
10835 ROAD TO THE CURE
SUITE 205
SAN DIEGO, CA 92121
Related Filers
LABORATORIES ABBOTT — 29 joint filings, latest 2011-12-16
QLT INC/BC — 4 joint filings, latest 2017-05-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ABSI Director 21,300 $8.21 $174.9K $148.9K 4 2026-07-06
TLSI CEO and President 1,077,683 $4.67 $5.03M $0 1 2026-07-01
KURA Director — $11.39 — $0 9 2026-06-04
TLSIW CEO and President 1,065,215 $0.89 $948.0K $350.7K 10 2026-05-18
Omega Therapeutics, Inc. (OMGA) Delisted Director — $0.14 — $0 3 2024-06-21
Prometheus Biosciences, Inc. (RXDX) Delisted Director 0 $199.92 $0 $0 4 2023-06-16
CHRS Director 0 $1.33 $0 -$966.8K 9 2021-01-13
ALIMERA SCIENCES INC (ALIM) Delisted Director — $5.54 — $0 3 2020-06-22
NOVELION THERAPEUTICS INC. (NVLN) Delisted Chief Executive Officer 4,384 — — $0 2 2017-05-11
Aegerion Pharmaceuticals, Inc. (AEGR) Delisted Chief Executive Officer — — — $0 3 2016-11-30
Receptos, Inc. (RCPT) Delisted Director 0 — — $0 3 2015-08-27
ABT Senior Vice President 172,123 $101.95 $17.55M -$7.07M 27 2011-12-16

Recent Filings

80 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-06 ABSI Buy (P) +12,900 $148.9K EDGAR
2026-07-01 TLSI Grant (A) +3,990 $15.4K EDGAR
2026-06-15 ABSI Grant (A) +8,400 $0 EDGAR
2026-06-08 ABSI Grant (A) +10,100 $0 EDGAR
2026-06-04 KURA Grant (A) — $0 EDGAR
2026-05-18 TLSIW Buy (P) +39,682 $102.8K EDGAR
2026-03-20 TLSIW Sell (S) −20,302 -$79.4K EDGAR
2026-02-23 TLSIW Buy (P) +30,487 $125.0K EDGAR
2025-11-25 TLSIW Grant (A) +550,000 $0 EDGAR
2025-07-09 ABSI Grant (A) — $0 EDGAR
Showing 1–10 of 80
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.